Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 1.00 |
| ▸ | PRKACA | P17612 | 6/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 1.00 |
| ▸ | AKT2 | P31751 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 3/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 3/20 | 1.00 |
| ▸ | PAK4 | O96013 | 3/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 3/20 | 1.00 |
| ▸ | PRKCG | P05129 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 3/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 1.00 |
| ▸ | GSK3A | P49840 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| A-443654 SCHEMBL29380923 | 1.00 | AKT1 (1.00) | AKT1PRKACAAKT3AKT2DAPK3 | |
| A-443654 SCHEMBL19867533 | 1.00 | AKT1 (1.00) | AKT1PRKACAAKT3AKT2DAPK3 | |
| A-443654 SCHEMBL29644958 | 0.89 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2DAPK3 | |
| A-443654 SCHEMBL2738467 | 0.89 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2DAPK3 | |
| A-443654 SCHEMBL6855479 | 0.89 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2DAPK3 | |
| A-443654 SCHEMBL19859268 | 0.89 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2DAPK3 | |
| A-443654 SCHEMBL29374078 | 0.89 | AKT1 (0.85) | AKT1PRKACAAKT3AKT2DAPK3 | |
| SCHEMBL2738468 | 0.87 | AKT1 (0.78) | AKT1PRKACAAKT3AKT2DAPK3 | |
| SCHEMBL6855274 | 0.86 | AKT1 (1.00) | AKT1PRKACAAKT3AKT2DAPK3 | |
| SCHEMBL6854290 | 0.84 | AKT1 (0.81) | AKT1PRKACAAKT3AKT2DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-2841075-B1 | AGENTS AND METHODS FOR TREATING AND PREVENTING SEBORRHEIC KERATOSIS | MASSACHUSETTS GEN HOSPITAL (US) | 2020-03-18 | — | — | EP | claimed |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4308691-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | Iovance Biotherapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2015-11-12 | — | — | US | disclosed |
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-2791101-A1 | TREATMENT OF INFLAMMATION | Vascular Biogenics Ltd. (IL) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013152193-A2 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013088245-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012019154-A2 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | CD14, TLR2, TLR4 | AKT1 542/4885PRKACA 451/4885AKT3 576/4885 |
| US-20150056215-A1 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | MDH2, MDH1, ME1 | AKT1 3009/4885PRKACA 2020/4885AKT3 2952/4885 |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | AKT1 108/4885PRKACA 2421/4885AKT3 82/4885 |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | CD69, CD209, ICOS | AKT1 4251/4885PRKACA 3732/4885AKT3 3236/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | AKT1 1236/4885PRKACA 3225/4885AKT3 1286/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | AKT1 1216/4885PRKACA 3496/4885AKT3 1098/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | AKT1 3945/4885PRKACA 4537/4885AKT3 4012/4885 |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IL15, IL15RA, ICOS | AKT1 108/4885PRKACA 2421/4885AKT3 82/4885 |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | AKT1 108/4885PRKACA 2421/4885AKT3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.